The aim of this study was to evaluate the effect of zoledronic acid (ZA) on bone mineral density (BMD) in patients with prostate cancer receiving combined androgen blockade (CAB) as a first-line androgen deprivation therapy.
Patients receiving CAB for prostate cancer without bone metastasis were candidates for this study. Forty-two patients were randomly assigned to receive either ZA or no treatment. BMD were measured at baseline and at 12 months. Bone-turnover markers, including cross-linked N-telopeptide of type I collagen (NTX), C-telopeptide of type I collagen (ICTP), and bone-specific alkaline phosphatase (BAP), were assessed during study periods. Patients on ZA maintained BMD after a year of treatment. Change in T-score from baseline differed significantly between the two groups (P=0.009). An inverse correlation was demonstrated between baseline and change in T-score in the ZA group. While ZA prevented an increase in ICTP and BAP, the increase in NTX was suppressed only in patients with low baseline T-score. ZA prevented a decrease in BMD in patients undergoing CAB, especially those with lower baseline BMD.
Written by:
Nishizawa S, Inagaki T, Iba A, Kikkawa K, Kodama Y, Matsumura N, Kohjimoto Y, Hara I. Are you the author?
Department of Urology, Wakayama Medical University School of Medicine, 811-1 Kimiidera, Wakayama, 641-8509 Japan; Department of Urology, Rinku General Medical Center, Osaka, Japan; Department of Urology, Kinan Hospital, Wakayama, Japan.
Reference: Springerplus. 2014 Oct 8;3:586.
doi: 10.1186/2193-1801-3-586
PubMed Abstract
PMID: 25332886